Information de reference pour ce titreAccession Number: | 01445491-201006000-00015.
|
Author: | Brownstein, John S. PhD 1; Green, Traci C. MSc, PhD 1; Cassidy, Theresa A. MPH 1; Butler, Stephen F. PhD 1, *, +
|
Institution: | (1)Inflexxion Inc., Newton MA, USA
|
Title: | |
Source: | Pharmacoepidemiology & Drug Safety. 19(6):627-637, June 2010.
|
Abstract: | Purpose: Understanding the spatial distribution of opioid abuse at the local level may facilitate public health interventions.
Methods: Using patient-level data from addiction treatment facilities in New Mexico from ASI-MV(R) Connect, we applied geographic information system (GIS) in combination with a spatial scan statistic to generate risk maps of prescription opioid abuse and identify clusters of product- and compound-specific abuse. Prescribed opioid volume data was used to determine whether identified clusters are beyond geographic differences in availability.
Results: Data on 24 452 patients residing in New Mexico were collected. Among those patients, 1779 (7.3%) reported abusing any prescription opioid (past 30 days). According to opioid type, 979 patients (4.0%) reported abuse of any hydrocodone, 1007 (4.1%) for any oxycodone, 108 (0.4%) for morphine, 507 (2.1%) for Vicodin(R) or generic equivalent, 390 (1.6%) for OxyContin(R), and 63 (0.2%) for MS Contin(R) or generic equivalent. Highest rates of abuse were found in the area surrounding Albuquerque with 8.6 patients indicating abuse per 100 interviewed patients. We found clustering of abuse around Albuquerque (P = 0.001; Relative Risk = 1.35, and a radius of 146 km). At the compound level, we found that drug availability was partly responsible for clustering of prescription opioid abuse. After accounting for drug availability, we identified a second foci of Vicodin(R) abuse in the southern rural portion of the state near Las Cruces, NM and El Paso, Texas and bordering Mexico (RR = 2.1; P = 0.001).
Conclusions: A better understanding of local risk distribution may have implications for response strategies to future introductions of prescription opioids. Copyright (C) 2010 John Wiley & Sons, Ltd.
Copyright (C) 2010 John Wiley & Sons, Inc.
|
Author Keywords: | cluster detection; geography; opioid abuse; post-marketing surveillance.
|
References: | 1. Dasgupta N, Kramer ED, Zalman MA, et al. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006; 82: 135-142.
2. Hopfer CJ, Mikulich SK, Crowley TJ. Heroin use among adolescents in treatment for substance use disorders. J Am Acad Child Adolesc Psychiatry 2000; 39: 1316-1323.
3. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006; 15: 618-627.
4. Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008; 17: 1142-1154.
5. Curtis LH, Stoddard J, Radeva JI, et al. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res 2006; 41: 837-855.
6. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006; 31: 506-511.
7. Dasgupta N, Jonsson Funk M, Brownstein J.S., Geography and Drug Addiction, Richardson TD, Cheung I (eds). Springer Publishers: (Collaboration between the National Institute on Drug Abuse and the Association of American Geographers), 2008; New York.
8. Havens JR, Walker R, Leukefeld CG. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend. 2007 Feb 23; 87(1): 98-102.
9. Leukefeld CG, Narevic E, Hiller ML, et al. Alcohol and drug use among rural and urban incarcerated substance abusers. Int J Offender Ther Comp Criminol 2002; 46: 715-728.
10. Schoeneberger ML, Leukefeld CG, Hiller ML, et al. Substance abuse among rural and very rural drug users at treatment entry. Am J Drug Alcohol Abuse 2006; 32: 87-110.
11. Paulozzi LJ. Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. Am J Public Health 2006; 96: 1755-1757.
12. Forrester MB. Oxycodone abuse in Texas, 1998-2004. J Toxicol Environ Health A 2007; 70: 534-538.
13. Havens JR, Talbert JC, Walker R, et al. Trends in controlled-release oxycodone (OxyContin) prescribing among Medicaid recipients in Kentucky, 1998-2002. J Rural Health 2006; 22: 276-278.
14. Brownstein JS, Rosen H, Purdy D, et al. Spatial analysis of West Nile virus: rapid risk assessment of an introduced vector-borne zoonosis. Vector Borne Zoonotic Dis 2002; 2: 157-164.
15. Glass GE. Update: spatial aspects of epidemiology: the interface with medical geography. Epidemiol Rev 2000; 22: 136-139.
16. Ostfeld RS, Glass GE, Keesing F. Spatial epidemiology: an emerging (or re-emerging) discipline. Trends Ecol Evol 2005; 20: 328-336.
17. Legendre P. Spatial autocorrelation: trouble or new paradigm? Ecology 1993; 74: 1659-1673.
18. Tobler WR. A computer model of simulating urban growth in the Detroit region. Economic Geography 1970; 46: 234-240.
19. Mueller MR, Shah NG, Landen MG. Unintentional prescription drug overdose deaths in New Mexico, 1994-2003. Am J Prev Med 2006; 30: 423-429.
20. Butler SF, Budman SH, Goldman RJ, et al. Initial validation of a computer-administered Addiction Severity Index: the ASI-MV. Psychol Addict Behav 2001; 15: 4-12.
21. Butler SF, Newman FL, Cacciola JS. Predicting ASI interviewer severity ratings for a computer-administered Addiction Severity Index. Psychological Assess 1998; 10: 399-407.
22. Wakefield JC, Kelsall JE, Morris SE. Spatial Epidemiology, Elliot P, Wakefield JC, Best NG, Briggs DJ (eds). Oxford University Press: New York, 2000.
23. Naus JI. The distribution of the size of the maximum cluster of points on a line. J Am Stat Assoc 1965; 60: 532-538.
24. Brownstein JS, Rosen H, Purdy D, et al. Spatial analysis of West Nile virus: rapid risk assessment of an introduced vector- borne zoonosis. Vector Borne & Zoonotic Diseases 2002; 2: 157-164.
25. Hjalmars U, Kulldorff M, Gustafsson G, et al. Childhood leukaemia in Sweden: using GIS and a spatial scan statistic for cluster detection. Stat Med 1996; 15: 707-715.
26. Kulldorff M. A spatial scan statistic. Commun Stat-Theor M 1997; 26: 1481-1496.
27. Kulldorff M, Feuer EJ, Miller BA, et al. Breast cancer clusters in the northeast United States: a geographic analysis. Am J Epidemiol 1997; 146: 161-170.
28. Sudakin DL, Power LE. Regional and temporal variation in methamphetamine-related incidents: applications of spatial and temporal scan statistics. Clin Toxicol 2009; 47: 243-246.
29. Hanson CE, Wieczorek WF. Alcohol mortality: a comparison of spatial clustering methods. Soc Sci Med 2002; 55: 791-802.
30. Kulldorff M, Nargarwalla N. Spatial disease clusters: detection and inference. Stat Med 1995; 14: 799-810.
31. Dwass M. Modified randomization tests for nonparametric hypotheses. Ann Math Stat 1957; 28: 181-187.
32. Smith MY, Schneider MF, Wentz A, et al. Quantifying morbidity associated with the abuse and misuse of opioid analgesics: a comparison of two approaches. Clin Toxicol (Phila) 2007; 45: 23-30.
33. ESRI. (ed. 9.2, A.) (2006).
34. US Census Bureau. (U.S. Dept. Commerce, Economics and Statistics Administration, Washington, D.C., 2001).
35. U.S. Department of Justice. (ed. National Drug Intelligence Center) (2002).
36. Poshyachinda V. Drug injecting and HIV infection among the population of drug abusers in Asia. Bull Narc 1993; 45: 77-90.
37. Kulsudjarit K. Drug problem in southeast and southwest Asia. Ann N Y Acad Sci 2004; 1025: 446-457.
38. Drug Enforcement Agency. Briefs and Backgrounds, state fact sheet: New Mexico. Available at: http://www.dea.gov/pubs/states/n...- ouverture dans une nouvelle fenêtre. 2007.
39. Seidler R. Prescription Drug Abuse: Opioids. Available at: http://www.nswrdn.com.au/client_...- ouverture dans une nouvelle fenêtre. Current Therapeutics. 2002: 33-35.
40. Degenhardt L, Black E, Breen C, et al. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev 2006; 25: 403-412.
41. O'Brien S, Black E, Roxburgh A, et al. Australian drug trends 2006: findings from the Illicit Drug Reporting System (IDRS). NDARC Monograph 60: 2007: 25-51.
42. Buehler JW, Hopkins RS, Overhage JM. Framework for evaluating public health surveillance systems for early detection of outbreaks: recommendations from the CDC working group. MMWR 2004; 53: 1-11.
43. Green TC, Brownstein JS, Butler SF. Geographic and contextual factors of prescription opioid abuse: Results from ASI-MV(R) Connect. Paper presented to the College on Problems of Drug Dependence (CPDD), Reno, NV, 2009, June 22.
44. Brands B, Blake J, Sproule B, et al. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend 2004; 73: 199-207.
45. Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007; 90: 64-71.
|
Language: | English.
|
Document Type: | Original Reports.
|
Journal Subset: | Pharmacology.
|
ISSN: | 1053-8569
|
DOI Number: | https://dx.doi.org/10.1002/pds.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|